Yu C C, Chen K K, Chen M T, Huang J K, Lin A T, Lee Y H, Chang L S
Department of Surgery, Veterans General Hospital-Taipei, Taiwan, Republic of China.
Eur Urol. 1991;19(1):54-8. doi: 10.1159/000473580.
To evaluate the feasibility of using serum iron as a tumor marker for renal cell carcinoma, a retrospective review of serum iron, hemoglobin, hematocrit, mean corpuscular volume and pathology in patients with renal cell carcinoma was carried out. From January 1985 to December 1989, preoperative serum iron was obtained in 82 patients; 27 had stage I, 5 stage II, 23 stage III and 27 had stage IV disease. The serum iron levels (micrograms/dl) were 81.6 +/- 33.2 in stage I, 57.8 +/- 18.9 in stage II, 59.6 +/- 34.6 in stage III and 45.6 +/- 32.7 in stage IV disease, which were significantly lower as compared with the data (114.6 +/- 38.9) of a control group. Postoperative serum iron levels were available in 31 patients following nephrectomy and all showed an increase as compared with preoperative data except 2: 1 with recurrence and the other with progression of disease. It was concluded that the serum iron level may be used as a useful tumor marker in staging and follow-up of renal cell carcinoma.
为评估血清铁作为肾细胞癌肿瘤标志物的可行性，对肾细胞癌患者的血清铁、血红蛋白、血细胞比容、平均红细胞体积及病理情况进行了回顾性分析。1985年1月至1989年12月期间，82例患者术前检测了血清铁；其中27例为Ⅰ期，5例为Ⅱ期，23例为Ⅲ期，27例为Ⅳ期。血清铁水平（微克/分升）在Ⅰ期为81.6±33.2，Ⅱ期为57.8±18.9，Ⅲ期为59.6±34.6，Ⅳ期为45.6±32.7，与对照组数据（114.6±38.9）相比显著降低。31例患者肾切除术后有术后血清铁水平数据，除2例（1例复发，1例疾病进展）外，其余患者术后血清铁水平均较术前升高。结论认为，血清铁水平可作为肾细胞癌分期及随访的有用肿瘤标志物。
